Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure

Jacob Joseph, Asem Rimawi, Paulette Mehta, Michele Cottler-Fox, Anjan Sinha, Balkrishnaman K. Singh, Rebecca Pacheco, Eugene S. Smith, Jawahar L. Mehta

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The objective of this study was to determine a safe and effective dose of granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with advanced heart failure and to determine its effects on the cytokine profile. Patients with advanced heart failure (n = 6) and implantable defibrillators in situ were administered G-CSF after baseline echocardiographic and laboratory evaluation, using an escalating dose schedule designed to ensure safety. The peripheral CD34+ hematopoietic stem cell count increased from 3.6 ± 0.5/μl to 38.7 ± 13/μl (p = 0.022) after 5 days of 5 μg/kg/day G-CSF therapy. The baseline or peak white blood cell count did not predict the stem cell response. G-CSF increased plasma levels of interleukin-10. Left ventricular ejection fraction increased significantly in the 4 patients with ischemic cardiomyopathy 9 months after treatment. No major adverse effects attributable to the drug occurred during administration or 9 months of follow-up. Our results have shown that low-dose G-CSF significantly mobilized hematopoietic stem cells in advanced heart failure and improved left ventricular function in the ischemic subset of patients. G-CSF significantly increased plasma levels of the anti-inflammatory cytokine interleukin-10, without changing pro-inflammatory cytokine levels. In conclusion, these results indicate a novel mechanism of action for the potential therapeutic benefit of G-CSF in advanced ischemic cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)681-684
Number of pages4
JournalThe American Journal of Cardiology
Volume97
Issue number5
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Stem Cells
Heart Failure
Cytokines
Safety
Hematopoietic Stem Cells
Cardiomyopathies
Interleukin-10
Implantable Defibrillators
Leukocyte Count
Left Ventricular Function
Stroke Volume
Action Potentials
Appointments and Schedules
Anti-Inflammatory Agents
Therapeutics
Cell Count
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. / Joseph, Jacob; Rimawi, Asem; Mehta, Paulette; Cottler-Fox, Michele; Sinha, Anjan; Singh, Balkrishnaman K.; Pacheco, Rebecca; Smith, Eugene S.; Mehta, Jawahar L.

In: The American Journal of Cardiology, Vol. 97, No. 5, 01.03.2006, p. 681-684.

Research output: Contribution to journalArticle

Joseph, Jacob ; Rimawi, Asem ; Mehta, Paulette ; Cottler-Fox, Michele ; Sinha, Anjan ; Singh, Balkrishnaman K. ; Pacheco, Rebecca ; Smith, Eugene S. ; Mehta, Jawahar L. / Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. In: The American Journal of Cardiology. 2006 ; Vol. 97, No. 5. pp. 681-684.
@article{43eb162cb5124f8a8cdfd9de2fca1dea,
title = "Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure",
abstract = "The objective of this study was to determine a safe and effective dose of granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with advanced heart failure and to determine its effects on the cytokine profile. Patients with advanced heart failure (n = 6) and implantable defibrillators in situ were administered G-CSF after baseline echocardiographic and laboratory evaluation, using an escalating dose schedule designed to ensure safety. The peripheral CD34+ hematopoietic stem cell count increased from 3.6 ± 0.5/μl to 38.7 ± 13/μl (p = 0.022) after 5 days of 5 μg/kg/day G-CSF therapy. The baseline or peak white blood cell count did not predict the stem cell response. G-CSF increased plasma levels of interleukin-10. Left ventricular ejection fraction increased significantly in the 4 patients with ischemic cardiomyopathy 9 months after treatment. No major adverse effects attributable to the drug occurred during administration or 9 months of follow-up. Our results have shown that low-dose G-CSF significantly mobilized hematopoietic stem cells in advanced heart failure and improved left ventricular function in the ischemic subset of patients. G-CSF significantly increased plasma levels of the anti-inflammatory cytokine interleukin-10, without changing pro-inflammatory cytokine levels. In conclusion, these results indicate a novel mechanism of action for the potential therapeutic benefit of G-CSF in advanced ischemic cardiomyopathy.",
author = "Jacob Joseph and Asem Rimawi and Paulette Mehta and Michele Cottler-Fox and Anjan Sinha and Singh, {Balkrishnaman K.} and Rebecca Pacheco and Smith, {Eugene S.} and Mehta, {Jawahar L.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.amjcard.2005.09.112",
language = "English (US)",
volume = "97",
pages = "681--684",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure

AU - Joseph, Jacob

AU - Rimawi, Asem

AU - Mehta, Paulette

AU - Cottler-Fox, Michele

AU - Sinha, Anjan

AU - Singh, Balkrishnaman K.

AU - Pacheco, Rebecca

AU - Smith, Eugene S.

AU - Mehta, Jawahar L.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - The objective of this study was to determine a safe and effective dose of granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with advanced heart failure and to determine its effects on the cytokine profile. Patients with advanced heart failure (n = 6) and implantable defibrillators in situ were administered G-CSF after baseline echocardiographic and laboratory evaluation, using an escalating dose schedule designed to ensure safety. The peripheral CD34+ hematopoietic stem cell count increased from 3.6 ± 0.5/μl to 38.7 ± 13/μl (p = 0.022) after 5 days of 5 μg/kg/day G-CSF therapy. The baseline or peak white blood cell count did not predict the stem cell response. G-CSF increased plasma levels of interleukin-10. Left ventricular ejection fraction increased significantly in the 4 patients with ischemic cardiomyopathy 9 months after treatment. No major adverse effects attributable to the drug occurred during administration or 9 months of follow-up. Our results have shown that low-dose G-CSF significantly mobilized hematopoietic stem cells in advanced heart failure and improved left ventricular function in the ischemic subset of patients. G-CSF significantly increased plasma levels of the anti-inflammatory cytokine interleukin-10, without changing pro-inflammatory cytokine levels. In conclusion, these results indicate a novel mechanism of action for the potential therapeutic benefit of G-CSF in advanced ischemic cardiomyopathy.

AB - The objective of this study was to determine a safe and effective dose of granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells in patients with advanced heart failure and to determine its effects on the cytokine profile. Patients with advanced heart failure (n = 6) and implantable defibrillators in situ were administered G-CSF after baseline echocardiographic and laboratory evaluation, using an escalating dose schedule designed to ensure safety. The peripheral CD34+ hematopoietic stem cell count increased from 3.6 ± 0.5/μl to 38.7 ± 13/μl (p = 0.022) after 5 days of 5 μg/kg/day G-CSF therapy. The baseline or peak white blood cell count did not predict the stem cell response. G-CSF increased plasma levels of interleukin-10. Left ventricular ejection fraction increased significantly in the 4 patients with ischemic cardiomyopathy 9 months after treatment. No major adverse effects attributable to the drug occurred during administration or 9 months of follow-up. Our results have shown that low-dose G-CSF significantly mobilized hematopoietic stem cells in advanced heart failure and improved left ventricular function in the ischemic subset of patients. G-CSF significantly increased plasma levels of the anti-inflammatory cytokine interleukin-10, without changing pro-inflammatory cytokine levels. In conclusion, these results indicate a novel mechanism of action for the potential therapeutic benefit of G-CSF in advanced ischemic cardiomyopathy.

UR - http://www.scopus.com/inward/record.url?scp=32844457977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32844457977&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.09.112

DO - 10.1016/j.amjcard.2005.09.112

M3 - Article

VL - 97

SP - 681

EP - 684

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -